Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
Not yet recruiting · NCT07542678 · Registry updated 2026-04-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept | Relapsed /Refractory DLBCL | Not yet recruiting | Phase 2 | 2026-04-21 | NCT07542678 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin | Berlin | Germany | 1 |
| Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und Klinische Immunologie | Düsseldorf | Germany | 2 |
| Universitätsklinikum Essen (AöR) - Westdeutsches Tumorzentrum Essen - Klinik für Hämatologie und Stammzellltransplantation | Essen | Germany | 1 |
| Universitätsklinikum Heidelberg - Innere Medizin V | Heidelberg | Germany | 1 |
| Universitätsklinikum Münster - Medizinische Klinik A | Münster | Germany | 1 |